NCT02614508View on ClinicalTrials.gov

Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic Lymphoma
Interventions
DRUG

Buparlisib

Given PO

DRUG

Ibrutinib

Given PO

BIOLOGICAL

Ofatumumab

Given IV

Trial Locations (1)

30322

Emory University/Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Emory University

OTHER

NCT02614508 - Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter